Loading...
Loading...
SBTX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.1M |
| Gross Profit | -1.1M |
| Operating Expense | 18.6M |
| Operating I/L | -16.8M |
| Other Income/Expense | -1.1M |
| Interest Income | 1.1M |
| Pretax | -17.9M |
| Income Tax Expense | 1.1M |
| Net Income/Loss | -18.9M |
Silverback Therapeutics, Inc. is a biopharmaceutical company specializing in the development of tissue-targeted therapeutics for chronic viral infections, cancer, and other serious diseases. Their flagship product, SBT8230, is designed to combat chronic hepatitis B virus infection by stimulating an anti-viral immune response through targeted TLR8 activation in the liver. By leveraging this innovative approach, the company aims to generate revenue through the commercialization of their therapeutic products, addressing significant unmet medical needs in the treatment of various diseases.
